Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021年5月26日
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021年5月26日
Similarities and differences between SNDS and other claim databases
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021年5月25日
Using Authoring Templates to Write the Right Way
Creating submission-ready regulatory documents that are consistent in presentation, appropriate in content, and formatted to…
Jim Gallagher2021年5月25日
Overview of SNDS and the key working practices to access the database and ongoing SNDS developments
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021年5月25日
PBPK modeling approaches to assess risks associated with bioequivalence in drug development
In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed: Opportunities and challenges in conducting…
Jim Gallagher2021年5月19日
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Watch this presentation to learn • Overview of the SNDS and the key working practices…
Jim Gallagher2021年5月7日
The Wizard of Oligos: There’s no place like having a successful drug development program!
Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…
Jim Gallagher2021年4月30日
The Promises and Pitfalls of Gene Therapy for Rare Diseases
The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have…
Jim Gallagher2021年4月29日
Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Jim Gallagher2021年4月21日
